文献速递毛发、甲与色素性疾病

儿童斑秃与JAK抑制剂:弥合证据与实践的差距

Pediatric alopecia areata and JAK inhibitors: Bridging the gap between evidence and practice.
PubMed 文献 · J Am Acad Dermatol · 2026-09-11

本文是一篇临床综述,总结儿童斑秃(AA)使用JAK抑制剂(JAKis)的现有证据与临床经验。目前仅ritlecitinib获FDA批准用于≥12岁儿童AA,多数JAKi在儿童中为超说明书使用;多种JAKi显示有意义的毛发再生且安全性总体良好。综述旨在为JAKi选择、剂量、安全监测和临床实施提供实用指导。

要点

  • ritlecitinib是唯一获FDA批准用于≥12岁儿童AA的JAKi,其余JAKi在儿童中多为超说明书使用。
  • 多种JAKi(如abrocitinib、baricitinib、ritlecitinib、tofacitinib等)在儿童AA中显示有意义的毛发再生,安全性总体良好。
  • 合并特应性或自身免疫病、IgE升高和嗜酸性粒细胞增多的儿童可能从JAKi中获益更多。

核心结论

  • JAKis在儿童AA中显示有意义的毛发再生且安全性总体良好,但多数为超说明书使用,需结合现有证据与临床经验进行个体化选择与监测。

研究设计与样本

  • 本文为临床综述,综合当前证据与临床经验,聚焦儿童AA的JAKi选择、剂量、安全监测及实施考虑。

主要发现

  • ritlecitinib是唯一获美国FDA批准用于儿童AA(≥12岁)的JAKi,多数JAKi在儿童中为超说明书使用。
  • abrocitinib、baricitinib、deuruxolitinib、ritlecitinib、ruxolitinib、tofacitinib和upadacitinib在儿童AA中显示有意义的毛发再生,安全性总体良好。
  • JAKis可能对合并特应性或自身免疫病的儿童尤其有益,也可能对IgE升高和嗜酸性粒细胞增多的患者有作用。
  • 早发和严重疾病可能值得更早考虑系统治疗。

关键数值与推荐

  • ritlecitinib获FDA批准用于≥12岁儿童AA,是唯一获批的JAKi。
  • 多种JAKi(abrocitinib、baricitinib、deuruxolitinib、ritlecitinib、ruxolitinib、tofacitinib、upadacitinib)在儿童AA中显示有意义的毛发再生。

临床怎么用

  • 临床可根据现有证据与经验选择JAKi,并关注剂量、安全监测及在儿童AA中的实施要点。
  • 对合并特应性或自身免疫病、IgE升高和嗜酸性粒细胞增多的儿童,可考虑JAKi治疗。
  • 对早发和严重疾病,可更早考虑系统治疗。

局限性

  • 不同报告和研究之间的结局报告存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alopecia areata (AA) is a chronic immune-mediated disorder characterized by nonscarring hair loss that frequently begins in childhood and is associated with substantial psychosocial burden. Therapeutic options for pediatric AA remain limited, particularly for patients with extensive or treatment-resistant disease. Janus kinase-inhibitors (JAKis) have emerged as promising targeted therapies that interrupt the JAK-STAT signaling pathway central to AA pathogenesis. Currently, ritlecitinib is the only U.S. Food and Drug Administration-approved JAKi for pediatric AA (≥12 years), leaving most JAKi use in children off-label. Despite this, emerging evidence and clinical experience demonstrate meaningful hair regrowth in pediatric patients treated with several JAKis, including abrocitinib, baricitinib, deuruxolitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib, with generally favorable safety profiles. Additionally, evidence suggests that JAKis may be particularly beneficial in children with concomitant atopic or autoimmune disease and may also play a role in patients with elevated IgE levels and eosinophilia. Early-onset and severe disease may also warrant earlier consideration of systemic therapy. Limitations include heterogeneous outcome reporting between various reports and studies. Overall, this clinical review synthesizes current evidence and clinical experience to provide practical guidance on JAKi selection, dosing, safety monitoring, and key considerations for implementing these therapies in pediatric AA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Hill MA, Irfan M, Bergfeld W, et al. Pediatric alopecia areata and JAK inhibitors: Bridging the gap between evidence and practice. J Am Acad Dermatol. 2026. PMID: 42727783. doi:10.1016/j.jaad.2026.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。